Immatics Final logo (R)_white_background.png
Immatics Announces Pricing of $175 Million Public Offering
January 17, 2024 20:30 ET | https://immatics.com/
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Final logo (R)_white_background.png
Immatics Announces Proposed Public Offering
January 17, 2024 16:01 ET | https://immatics.com/
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Final logo (R)_white_background.png
Immatics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023 07:00 ET | https://immatics.com/
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including...
Immatics Final logo (R)_white_background.png
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
November 08, 2023 07:00 ET | https://immatics.com/
Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for...
Immatics Final logo (R)_white_background.png
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
October 24, 2023 07:00 ET | https://immatics.com/
  RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities...
Moderna and Immatics
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
September 11, 2023 07:00 ET | https://immatics.com/
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® moleculesCompanies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s...
Moderna und Immatics
Moderna und Immatics geben strategische Multi-Plattform-Kollaboration zur Entwicklung innovativer Onkologie Therapeutika bekannt
September 11, 2023 07:00 ET | Immatics N.V.
Kollaboration kombiniert führende Technologien zur Entwicklung bahnbrechender, in vivo exprimierter mRNA TCER®-MoleküleDie Unternehmen werden zur Entwicklung neuartiger Krebsimpfstoffe Immatics...
Immatics Announces S
Immatics Announces Second Quarter 2023 Financial Results and Business Update
August 17, 2023 07:00 ET | https://immatics.com/
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME...
Immatics veröffentli
Immatics veröffentlicht Ergebnisse des zweiten Quartals 2023 sowie ein Update zur Geschäftsentwicklung
August 17, 2023 07:00 ET | Immatics N.V.
Klinische Phase-1/2-Studie zur Untersuchung von Immatics‘ zweitem bispezifischen TCR-Programm der nächsten Generation mit verlängerter Halbwertszeit, TCER® IMA402 (Zielstruktur: PRAME),...
Immatics Initiates P
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
August 10, 2023 07:00 ET | https://immatics.com/
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinicPatient enrollment for IMA402 Phase 1/2 trial underwayThe trial will evaluate safety,...